Agenus Inc. Net Aquisitions

Net Aquisitions of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Aquisitions growth rates and interactive chart.


Highlights and Quick Summary

  • Net Aquisitions for the quarter ending June 29, 2020 was $-972 Thousand (a -86.47% decrease compared to previous quarter)
  • Year-over-year quarterly Net Aquisitions decreased by -Infinity%
  • Annual Net Aquisitions for 2015 was $-7.18 Million (a -1495.94% decrease from previous year)
  • Twelve month Net Aquisitions ending June 29, 2020 was $-8.15 Million (a 13.53% increase compared to previous quarter)
Trailing Net Aquisitions for the last four month:
29 Jun '20 30 Dec '15 30 Dec '14
$-8.15 Million $-7.18 Million $515 Thousand
Visit stockrow.com/AGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Aquisitions of Agenus Inc.

Most recent Net Aquisitionsof AGEN including historical data for past 10 years.

Interactive Chart of Net Aquisitions of Agenus Inc.

Agenus Inc. Net Aquisitions for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-0.97
2015 $-7.18 $-7.18
2014 $0.0 $0.0 $0.0 $0.51 $0.51

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.